GlaxoSmithKline (GSK) announced that it has sold two thrombosis brands and a French plant to South African company Aspen for 700 million. "GSK today announced it has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the Notre-Dame de Bondeville manufacturing site to The Aspen Group," said a statement. "The agreement is a further example of GSK's commitment to increase focus on products with the most growth potential," it ...
via Medindia Health News More READ
No comments:
Post a Comment